Prellis Biologics: Antibody Discovery with AI & Immune DiversityPrellis Biologics: Antibody Discovery with AI & Immune DiversityPrellis Biologics: Antibody Discovery with AI & Immune DiversityContacts
linked inX - twitter

Bio AI: Harnessing human diversity and AI to build next-generation medicines

Integrating human biology with machine learning

We aim to revolutionize drug discovery by harnessing the power of the human immune system with tightly-integrated machine learning to develop next-generation antibody therapeutics with unparalleled speed, precision, and safety. We are committed to empowering our pharmaceutical partners with access to the most promising fully human antibody candidates, rapidly identified from the full human immune repertoire, enabling them to bring life-changing treatments to patients faster than ever before.

Our Team

Our Investors

Celesta Capital (WRVI)Khosla VenturesAvidity PartnersSOSVBlack DiamondFuture VenturesTrue Ventures

Prellis engages in the strategic collaborations to advance next-generation antibody therapies

Partner With Us